Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 and SHR-9839 with Adebrelimab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT07059221Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102, SHR-9839 in head and neck squamous cell carcinoma (HNSCC), sponsored by Suzhou Suncadia Biopharmaceutical. Started Jul 2025; status: recruiting.
02
Drugs
SHR-A2102SHR-9839
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07059221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059221.